Weekender 4/22/16

This week’s edition of the Weekender is a testament to the amazing innovation taking place within the Garden State with many exciting announcements from emerging companies, such as BioNJ Members ContraVir Pharmaceuticals, SCYNEXIS, Cyclacel Pharmaceuticals, Caladrius Biosciences, PTC Therapeutics, PDS Biotechnology, Soligenix, Advaxis, ProStrakan, Immunomedics and more. From new drug approvals to reaching important milestones… Read the full article


Weekender 4/8/16

NJ Spotlight’s recent article entitled “Can Biotechnology Provide the Cure for What Ails New Jersey’s Economy?” stated, “New Jersey can rightfully call itself the undisputed global leader in biopharmaceuticals.” This week’s edition of the BioLines Weekender is a true testament to this statement — brimming with stories of innovation, partnerships and hope. In honor of… Read the full article


Weekender 3/25/16

Because Patients Can’t WaitSM, BioNJ hosted its first ever Patient Advocacy Team Briefing with guest speakers from the Hypertrophic Cardiomyopathy Association, the National Alliance of Mental Illness and the Myelodysplastic Syndromes Foundation who shared their experiences with our Team. Congratulations to BioNJ Members Elusys Therapeutics on the FDA approval of ANTHIM® (obiltoxaximab) injection, the company’s… Read the full article


Weekender 3/11/16

This edition of the BioLines Weekender once again features the wide breadth of innovation taking place within our State. Over the last two weeks, there were a number of new FDA designations and drug approvals going to BioNJ Members, including Allergan, Bristol-Myers Squibb, Matinas BioPharma, Merck and Novartis. See more below. With approximately 2,300 clinical… Read the full article


Weekender 2/26/16

In honor of “Rare Disease Day” on February 29, this edition of the BioLines Weekender is dedicated to the innovation being conducted at New Jersey companies working to bring therapies and cures to so many Patients who are waging courageous battles against approximately 7,000 Rare Diseases. These companies and these Patients inspire and enable our… Read the full article


Weekender 2/12/16

Thank you to New Jersey’s dynamic life sciences community for helping us celebrate the innovation coming from the Garden State during BioNJ’s 23rd Annual Dinner Meeting and Innovation Celebration that took place last week. The inspirational and moving evening set the stage for the important year ahead with so much happening on the national stage… Read the full article


Weekender 1/29/16

As we prepare to honor New Jersey’s Innovators that received drug approvals in 2015 at our upcoming Annual Dinner Meeting on February 4, the Garden State is off to a strong start again in 2016 with drug approvals over the last week going to BioNJ Members Genmab, Eli Lilly, Merck, Allergan and Bristol-Myers Squibb. Congrats! Meanwhile, a… Read the full article


Weekender 1/22/16

With 2016 in full swing, New Jersey’s vibrant life sciences ecosystem continues to do what it does best — bring new cures and therapies to the Patients who need them.    Congratulations to BioNJ Member Novartis Pharmaceuticals for receiving two new FDA approvals for Cosentyx to treat patients with Ankylosing Spondylitis and Psoriatic Arthritis. This is in addition… Read the full article


Weekender 1/8/16

With nearly 60% of all of last year’s FDA new drug approvals coming from companies with a footprint in New Jersey, the Garden State’s robust life sciences community has once again played a prominent role in delivering novel life-changing therapies and cures to Patients around the world. We look forward to even more innovation in the… Read the full article


Weekender 12/18/15

More promise for Patients as a result of the innovation coming out of New Jersey’s life sciences ecosystem… Breaking News: BioNJ President and CEO Debbie Hart was named to a list of 38 “Women of Power” in the most recent issue of HudsonMOD along with Diane Von Furstenberg, Ivanka Trump, Sandra E. Peterson, Sheri McCoy,… Read the full article